Drugs & Targets FDA grants Orphan Drug designation to elraglusib for soft tissue sarcomas September 13, 2024Vol.50 No.34
Drugs & Targets FDA seeks consumer representatives for the Oncologic Drugs Advisory Committee September 13, 2024Vol.50 No.34
Drugs & Targets FDA approves neoadjuvant/adjuvant Imfinzi for resectable NSCLC September 06, 2024Vol.50 No.33
Drugs & Targets FDA accepts Bristol Myers Squibb’s sBLA for Opdivo + Yervoy in unresectable HCC September 06, 2024Vol.50 No.33
Drugs & Targets FDA grants Imfinzi priority review and Breakthrough Therapy designation for limited-stage SCLC September 06, 2024Vol.50 No.33
Drugs & Targets FDA grants de novo authorization for PGDx elio plasma focus Dx, a kitted, pan-solid tumor liquid biopsy test August 09, 2024Vol.50 No.32
Trials & Tribulations Of adaptive and factorial designsA biostatistician’s interpretation of last week’s ODAC August 02, 2024Vol.50 No.31By Donald A. Berry
